Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Neon Healthcare Limited, Mill Studio Business Centre, Crane Mead, Ware, Hertfordshire, SG12 9PY, United Kingdom
ETOPOPHOS 100mg Powder for Solution for Injection.
| Pharmaceutical Form |
|---|
|
Powder for solution for injection. White to off-white dry powder. |
Each vial contains 113.6 mg etoposide phosphate equivalent to 100 mg etoposide.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Etoposide |
The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA-topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts. |
| List of Excipients |
|---|
|
Dextran 40 |
Type I glass vial with a butyl rubber stopper and flip-off aluminium seal. Packs of 1, 5, 10, 20, 25 vials.
Not all pack sizes may be marketed.
Neon Healthcare Limited, Mill Studio Business Centre, Crane Mead, Ware, Hertfordshire, SG12 9PY, United Kingdom
PL 45043/0038
Date of first authorisation: 23 May 1996
Date of latest renewal: 22 Jan 2007
| Drug | Countries | |
|---|---|---|
| ETOPOPHOS | Australia, Estonia, France, New Zealand, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
